| scholarly article | Q13442814 |
| P50 | author | Juergen Reichardt | Q42699215 |
| P2093 | author name string | E. di Salle | |
| N. M. Makridakis | |||
| P433 | issue | 5 | |
| P921 | main subject | testosterone biosynthetic process | Q14905664 |
| Steroid 5 alpha-reductase 2 | Q4048886 | ||
| P304 | page(s) | 407–413 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | Pharmacogenetics and Genomics | Q10534561 |
| P1476 | title | Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II | |
| P478 | volume | 10 |
| Q47621371 | A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH. |
| Q35908949 | A renaissance of "biochemical genetics"? SNPs, haplotypes, function, and complex diseases. |
| Q35964705 | Agents in development for prostate cancer prevention |
| Q43888278 | Allelic frequencies of six polymorphic markers for risk of prostate cancer |
| Q34187652 | Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia |
| Q34110419 | Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention |
| Q41684535 | Association between SRD5A2 rs523349 and rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis |
| Q45265466 | Association between hormonal genetic polymorphisms and early-onset prostate cancer |
| Q37151872 | Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. |
| Q46474992 | Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer |
| Q36115601 | Biomarkers for the detection and prognosis of prostate cancer |
| Q92307648 | Characterising SRD5A2 Gene Variants in 37 Indonesian Patients with 5-Alpha-Reductase Type 2 Deficiency |
| Q33569564 | Characterization of the oestrogenic activity of non-aromatic steroids: are there male-specific endogenous oestrogen receptor modulators? |
| Q36458457 | Chemoprevention of prostate cancer with finasteride |
| Q51764443 | Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. |
| Q28360883 | Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer |
| Q44830215 | Compound heterozygous mutations in the SRD5A2 gene exon 4 in a male pseudohermaphrodite patient of Chinese origin |
| Q37155532 | Consortium analysis of 7 candidate SNPs for ovarian cancer |
| Q30628266 | Data mining: Efficiency of using sequence databases for polymorphism discovery |
| Q40279425 | Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines |
| Q36087271 | Environmental and genetic contributors to hypospadias: a review of the epidemiologic evidence |
| Q44441033 | Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer |
| Q36700397 | Exploration of gene-environment interactions, maternal effects and parent of origin effects in the etiology of hypospadias |
| Q28547130 | Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial |
| Q37818297 | Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. |
| Q51545723 | Five novel mutations of SRD5A2 found in eight Chinese patients with 46,XY disorders of sex development |
| Q30388880 | Gene changes may minimize masculinizing and defeminizing influences of exposure to male cotwins in female callitrichine primates |
| Q40505369 | Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride |
| Q38368023 | Genetic and environmental factors in the aetiology of hypospadias. |
| Q35044012 | Genetic and epigenetic factors: Role in male infertility |
| Q42352023 | Genetic sequencing of a patient with Kallmann syndrome plus 5α-reductase type 2 deficiency |
| Q38460006 | Genetics of androgen metabolism in women with infertility and hypoandrogenism |
| Q36845131 | Genomic biomarkers, androgen pathway and prostate cancer. |
| Q36512512 | Genomics in breast and prostate cancer: assessment of the current state and future perspectives. |
| Q33823048 | Genotyping the High Altitude Mestizo Ecuadorian Population Affected with Prostate Cancer |
| Q91496974 | Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT |
| Q43109397 | Gleason grading controversies: what the chemoprevention trials have taught us. |
| Q34732880 | Hormones and prostate cancer: current perspectives and future directions |
| Q41895812 | Hypospadias and variants in genes related to sex hormone biosynthesis and metabolism |
| Q45028275 | Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue |
| Q91579534 | Identification of three novel SRD5A2 mutations in Chinese patients with 5α-reductase 2 deficiency |
| Q38620751 | Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview. |
| Q94452943 | Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide |
| Q52611690 | Longer TA repeat but not V89L polymorphisms in the SRD5A2 gene may confer acne risk in the Chinese population. |
| Q36395111 | Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer |
| Q26774221 | Mechanisms of resistance in castration-resistant prostate cancer (CRPC) |
| Q47102773 | Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels |
| Q41552618 | Molecular basis of non-syndromic hypospadias: systematic mutation screening and genome-wide copy-number analysis of 62 patients. |
| Q36689955 | Neural Androgen Receptors Modulate Gene Expression and Social Recognition But Not Social Investigation. |
| Q37294754 | No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned |
| Q35753329 | Pharmacogenetics of human androgens and prostate cancer--an update. |
| Q34189642 | Pharmacogenetics of human androgens and prostatic diseases |
| Q41032833 | Phenotype and molecular characteristics in 45 Chinese children with 5α-reductase type 2 deficiency from South China |
| Q47903635 | Phenotype, genotype and gender identity in a large cohort of patients from India with 5α-reductase 2 deficiency |
| Q36456146 | Prostate cancer detection strategies |
| Q46718150 | SRD5A2 gene analysis in an Italian population of under-masculinized 46,XY subjects |
| Q50534098 | SRD5A2 gene mutations and polymorphisms in Spanish 46,XY patients with a disorder of sex differentiation. |
| Q45101790 | Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk |
| Q37305883 | Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial |
| Q37163160 | Sex dependent influence of a functional polymorphism in steroid 5-α-reductase type 2 (SRD5A2) on post-traumatic stress symptoms |
| Q46951247 | Significant impact of 5alpha-reductase type 2 polymorphisms on sperm concentration and motility |
| Q37633264 | Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review |
| Q101038372 | Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride |
| Q43946560 | Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols |
| Q40120927 | The new insight of prostate-specific antigen reduction during finasteride therapy in aging men. |
| Q80063335 | Unexpected biochemical and pharmacogenetic consequences of SNPs and haplotypes: a cautionary tale for human molecular genetics and epidemiology |
| Q33658285 | Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention |
Search more.